OpenAI Announces New Guaranteed Capacity Offering to Address Customer Compute Demand
Tepid Demand at US Treasury Auction Reflects Geopolitical Concerns Over Iran
CIBC CM Crushes Q1 2026 Estimates EPS 276 Tops Views
SpaceX IPO Plans Signal Massive Investment in Rockets and AI
Chinas Robotics Push Poses Competitive Challenge for Global Players Musk Says
Smaller Bitcoin Treasuries Increase Holdings by 603 BTC Amid Pause in Major Accumulation Strategy
India Diversifies Crude Oil Sourcing with Increased Reliance on Russia Brazil and Venezuela
Diamondback Energy Rides Oil Price Surge as Geopolitical Unrest Drives Sector Volatility
Oil and LNG Tankers Depart Strait of Hormuz Bound for Pakistan and China
Nvidia Stock Approaches Key Level as Market Watchers Eye Potential Breakout
Commercecom Inc Series 1 CMRC Q1 2026 Earnings EPS Surges Past Estimates Amid Undisclosed Revenue
CBFV Q1 2026 Earnings EPS Beats Estimates by 181 as Stock Remains Unchanged
CSR Q1 2026 Earnings Widely Misses EPS Estimates Stock Declines
CARE Q1 2026 Earnings EPS Falls 857 Below Consensus Shares Slip
BRBS Q1 2026 Earnings Positive EPS Surprise Amid Market Headwinds
Lucid Diagnostics Inc Q1 2026 Earnings WiderThanExpected Loss as PreRevenue Diagnostics Firm Advances Product Commercialization
Aytu BioPharma Gains 164 as Stock Tests Key Resistance at 228
Petrobras PBR Slips 269 as Oil Sector Headwinds Pressure Shares
Expro Group Holdings XPRO Declines 179 Approaching Critical Support at 1407
Gain Therapeutics GANX Bounces Back Testing Key Resistance at 187
Flowserve FLS Gains 128 as Technical Levels Point to Potential Upside
Post Office Horizon Scandal Inquiry Faces Critical Funding Crisis FiveYear Delay Looms
JILL Q1 2026 Earnings EPS Beats Estimates Despite Loss Stock Rises
DuPont DD Plunges 39 as Key Support Level Approaches What Investors Should Know
Dollar Tree Inc DLTR Fiscal 2027 Q1 Earnings Preview Resilient Value Play Poised for Margin Upside
Is Amneal AMRX stock testing support Amneal posts 557 pct EPS beat vs street estimates
TCRT Alaunos Therapeutics posts wider Q4 2023 loss than analyst estimates with shares slipping 039 percent in todays trading
Merck Co MRK Upgraded 2026 Guidance and HIV Drug Approval Reinforce But Do Not Reshape LongTerm Investment Thesis
What would it take for Canterbury CPHC to double from here Buying Pressure 20260508
What Grupo OMAB segment performance reveals Grupo posts 121 EPS miss vs Street estimates
TAL TAL Stock Future Potential Review 1852 EPS beat trounces analyst earnings estimates